PD-1/PD-L1 and PD-1/PD-L2 interactions inhibit effector T-cell function and are dominant in the peripheral tissues and tumor microenvironments (Parry et al., 2005; Keir et al., 2006; Weber, 2010; Wei et al., 2018). The gene discussed is PDCD1; the disease is neoplasm.